Analysts polled by Capital IQ expected $0.09.
Revenue for the quarter ended March 31 increased to $783.5 million from $696.5 million.
Four analysts polled by Capital IQ projected $692.7 million.
The company continues to expect EPS of $3.90 to $4.10 for full-year 2022. Analysts polled by Capital IQ are expecting $4.01.
|Insider Sell: Jazz Pharmaceuticals|
|Estee Lauder Lifts Restructuring Cost Estimate to Be...|
|Sierra Oncology Shareholders Approve Acquisition by GSK|
|Insider Sell: Factset Research Systems|
|Insider Sell: Liberty Global|